Is HRMY or HUMA more undervalued in 2026?

CirclFi compares Harmony Biosciences Holdings, I (HRMY) and Humacyte, Inc. (HUMA) using 13 institutional-grade valuation models. HRMY has a Quality of Company score of 10.0/10 while HUMA scores 3.5/10.

Which is a better buy — HRMY or HUMA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HRMY and HUMA valuations compare?

HRMY at $31.49 and HUMA at $1.28 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HRMY vs HUMA Valuation Comparison 2026 — Intrinsic Value Analysis

HRMY

Biotechnology

Harmony Biosciences Holdings, I

Quality

10.0

out of 10

Value Trap

SAFE

Price

$31.49

Last close

Models

12/13

Active

HUMA

Biotechnology

Humacyte, Inc.

Quality

3.5

out of 10

Value Trap

LOW

Price

$1.28

Last close

Models

5/13

Active

Model-by-Model Comparison

Model	Type	HRMY Fair Value	HRMY Upside	HUMA Fair Value	HUMA Upside
Bayesian DCF	Intrinsic	$97.76	+210.5%	$0.35	-73.0%
Earnings Power Value	Intrinsic	$23.18	-26.4%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$13.68	-56.6%	$0.36	-72.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HRMY vs HUMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HRMY vs HUMA — Which Stock Is More Undervalued?

HRMY scores higher with a 10.0/10 quality rating vs HUMA's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Harmony Biosciences Holdings, I (HRMY) and Humacyte, Inc. (HUMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HRMY currently trades at $31.49 with a QOC of 10.0/10, while HUMA trades at $1.28 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).